Novo Nordisk A/S - Product Pipeline Review - 2014

Published: Jun, 2014 | Pages: 97 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Novo Nordisk A/S - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Novo Nordisk A/S - Product Pipeline Review - 2014', provides an overview of the Novo Nordisk A/S's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Novo Nordisk A/S's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Novo Nordisk A/S including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Novo Nordisk A/S's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Novo Nordisk A/S's pipeline products

Reasons to buy

- Evaluate Novo Nordisk A/S's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Novo Nordisk A/S in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Novo Nordisk A/S's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Novo Nordisk A/S and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Novo Nordisk A/S
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Novo Nordisk A/S and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 6
Novo Nordisk A/S Snapshot 7
Novo Nordisk A/S Overview 7
Key Information 7
Key Facts 7
Novo Nordisk A/S - Research and Development Overview 8
Key Therapeutic Areas 8
Novo Nordisk A/S - Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products - Monotherapy 12
Pipeline Products - Combination Treatment Modalities 13
Pipeline Products - Partnered Products 14
Partnered Products/Combination Treatment Modalities 15
Pipeline Products - Out-Licensed Products 16
Out-Licensed Products/Combination Treatment Modalities 17
Novo Nordisk A/S - Pipeline Products Glance 18
Novo Nordisk A/S - Late Stage Pipeline Products 18
Pre-Registration Products/Combination Treatment Modalities 18
Filing rejected/Withdrawn Products/Combination Treatment Modalities 19
Phase III Products/Combination Treatment Modalities 20
Novo Nordisk A/S - Clinical Stage Pipeline Products 21
Phase II Products/Combination Treatment Modalities 21
Phase I Products/Combination Treatment Modalities 22
Novo Nordisk A/S - Early Stage Pipeline Products 24
Discovery Products/Combination Treatment Modalities 24
Novo Nordisk A/S - Drug Profiles 25
(insulin degludec + insulin aspart) 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
(insulin degludec + liraglutide) 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
insulin degludec 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
liraglutide 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
turoctocog alfa 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
NN-1218 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
NN-7088 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
nonacog beta pegol 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
semaglutide 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
NN-8226 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
NN-8555 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
NN-8828 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Oral Insulin 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
concizumab 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
LAI-287 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
NN-1953 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
NN-1954 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
NN-1956 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
NN-8210 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
NN-9926 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
NN-9927 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
NN-9928 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
somatropin 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Drugs for Rheumatoid Arthritis and Inflammatory Diseases 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Immunotherapy for Type 1 Diabetes 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
semaglutide Microneedle Patch 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Novo Nordisk A/S - Pipeline Analysis 62
Novo Nordisk A/S - Pipeline Products by Target 62
Novo Nordisk A/S - Pipeline Products by Route of Administration 64
Novo Nordisk A/S - Pipeline Products by Molecule Type 65
Novo Nordisk A/S - Pipeline Products by Mechanism of Action 66
Novo Nordisk A/S - Recent Pipeline Updates 68
Novo Nordisk A/S - Dormant Projects 86
Novo Nordisk A/S - Discontinued Pipeline Products 87
Discontinued Pipeline Product Profiles 87
balaglitazone 87
coagulation factor XIII A-subunit (recombinant) 87
NN-1952 88
NN-1998 88
NN-7128 88
NN-7129 88
NN-8209 88
NN-8226 88
NN-9112 89
NN-9161 89
NN-9925 89
NNC126-0083 89
ragaglitazar 89
tifenazoxide 89
vatreptacog alfa (activated) 89
Novo Nordisk A/S - Company Statement 90
Novo Nordisk A/S - Locations And Subsidiaries 91
Head Office 91
Other Locations & Subsidiaries 91
Appendix 96
Methodology 96
Coverage 96
Secondary Research 96
Primary Research 96
Expert Panel Validation 96
Contact Us 97
Disclaimer 97

List of Tables
Novo Nordisk A/S, Key Information 7
Novo Nordisk A/S, Key Facts 7
Novo Nordisk A/S - Pipeline by Indication, 2014 9
Novo Nordisk A/S - Pipeline by Stage of Development, 2014 11
Novo Nordisk A/S - Monotherapy Products in Pipeline, 2014 12
Novo Nordisk A/S - Combination Treatment Modalities in Pipeline, 2014 13
Novo Nordisk A/S - Partnered Products in Pipeline, 2014 14
Novo Nordisk A/S - Partnered Products/ Combination Treatment Modalities, 2014 15
Novo Nordisk A/S - Out-Licensed Products in Pipeline, 2014 16
Novo Nordisk A/S - Out-Licensed Products/ Combination Treatment Modalities, 2014 17
Novo Nordisk A/S - Pre-Registration, 2014 18
Novo Nordisk A/S - Filing rejected/Withdrawn, 2014 19
Novo Nordisk A/S - Phase III, 2014 20
Novo Nordisk A/S - Phase II, 2014 21
Novo Nordisk A/S - Phase I, 2014 22
Novo Nordisk A/S - Discovery, 2014 24
Novo Nordisk A/S - Pipeline by Target, 2014 63
Novo Nordisk A/S - Pipeline by Route of Administration, 2014 64
Novo Nordisk A/S - Pipeline by Molecule Type, 2014 65
Novo Nordisk A/S - Pipeline Products by Mechanism of Action, 2014 67
Novo Nordisk A/S - Recent Pipeline Updates, 2014 68
Novo Nordisk A/S - Dormant Developmental Projects,2014 86
Novo Nordisk A/S - Discontinued Pipeline Products, 2014 87
Novo Nordisk A/S, Subsidiaries 91